Investor Update
Basel, 28 August 2006
Genentech and Biogene Idec announced positive results from a phase II trial of Rituxan in relapsing-remitting multiple sclerosis
Dear Investor,
Please find attached a Genentech news release announcing that a Phase II study of Rituxan (Rituximab) for relapsing-remitting multiple sclerosis (RRMS) met its primary endpoint.
Please do not hesitate to contact us if you have any further questions.
Genentech and Biogene Idec announced positive results from a phase II trial of Rituxan in relapsing-remitting multiple sclerosis
Dear Investor,
Please find attached a Genentech news release announcing that a Phase II study of Rituxan (Rituximab) for relapsing-remitting multiple sclerosis (RRMS) met its primary endpoint.
Please do not hesitate to contact us if you have any further questions.